Looking for opportunity in energy? Mad Money host Jim Cramer may have finally found the spot.
The future of transportation and biotech, featuring Klaus Kleinfeld, of Alcoa; Mike McNamara, Flextronics International; ron Cohen, Acorda Therapeutics; Dr. Francois Nader, NPS Pharmaceuticals; Dr. Helen Torley, Halozyme Therapeutics; Tim Mayleben, Esperion Therapeutics; Stanley Erck, Novavax; John Orwin, Relypsa; Faheem Hasnain, Receptos; Shane Kovacs, PTC Therapeutics; and JJ Bienaime, Biomarin Pharmaceutical.
Mad Money host Jim Cramer shares his thoughts of on Bill Johnson, former CEO of Heinz, joining the board of PepsiCo.
Happy medium? Mad Money's Jim Cramer says it's where oil stops going down for a while and lets the market catch its breath.
Mad Money host Jim Cramer looks ahead to next week's earnings, events, and data that will impact the market.
The Fast Money traders discuss Alibaba and whether they're comfortable with the stock, and how it compares to Amazon.
Following the Swiss franc fallout, Jens Nordvig, Nomura Securities, sees a key indicator of panic in another global currency.
The "Fast Money" traders give their 7 best ways to play the Swiss Franc fallout.
Earnings and economic data all take a back seat to the European Central Bank in the week ahead.
Chris Lafakis, Moody's Analytics, predicts $80 oil by the end of 2015 based on supply and demand.
Nicholas Carlson, Business Insider; "Shark Tank" investor Kevin O'Leary; "Fast Money" trader Brian Kelly and CNBC's Robert Frank discuss this week's trading activity and where oil prices are headed.
David Darst, Investment Consultant, looks at factors that may determine how the market will trade.
Dissecting current market conditions and the impact "rumormongers" have on trade, with Art Cashin of UBS, and CNBC's Bob Pisani.
"Street Signs" hosts Mandy Drury and Brian Sullivan look at 5 stocks with analyst recommendations, including mostly bullish analyst comments for the new Quorvo.
CNBC's Bob Pisani reports on stability in the markets.
CNBC's Rick Santelli reports the latest consumer sentiment data.
The legal overhang on banks seems wrong to me, says CNBC's Jim Cramer in discussing some of the challenges facing the big banks.
Is the market about to rollover? CNBC's Jim Cramer explains why he is watching biotech closely.
CNBC's Bob Pisani reports FXCM has halted trading, and digs into the performance of the energy and financial sectors.
CNBC's Bob Pisani reports from the FXCM post where trading has been halted. Pisani explains the brokerage firm's situation. CNBC's David Faber provides insight on the "black swan" event.